InsiderPulse
Dashboard

IMVT

Immunovant, Inc.

Health CareRussell 2000

Immunovant, Inc. insider trading

Immunovant, Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in Durham, NC. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent IMVT insider transactions

6 insiders traded IMVT on the open market between Jun 15, 2026 and Aug 28, 2026 — 24 sales worth $4.5M, of which 4 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$4.5M

4 of 24 on a 10b5-1 plan

Net
−$4.5M
Insiders
6

Open-market purchases (code P) and sales (code S) from Immunovant, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every IMVT Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

IMVT insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 16 insiders traded IMVT on the open market: 2 purchases worth $686.9M and 118 sales worth $21.5M, 12 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 1 purchase ($350M) and 48 sales ($15M), by 11 insiders.

QuarterBoughtSold
Q2 2026—−$13.1M25 sales · 4 on a plan
Q1 2026—−$245.4K7 sales
Q4 2025+$350M1 buy−$1.6M12 sales · 4 on a plan
Q3 2025—−$140.4K4 sales
Q2 2025—−$885.5K9 sales
Q1 2025+$336.9M1 buy−$1.2M17 sales · 2 on a plan
Q4 2024—−$2.2M16 sales · 2 on a plan
Q3 2024—−$2.1M28 sales
Largest purchase
+$350M of IMVT by Roivant Sciences Ltd. (Director · 10% Owner) on Dec 12, 2025.
Largest sale
−$7.1M of IMVT by Fromkin Andrew J. (Director) on May 28, 2026.

Open-market transactions through Jun 30, 2026most recent first

  • Fromkin Andrew J.

    Director

    −$7.1M

    May 28, 2026

    210,468 sh · $33.56

  • Fromkin Andrew J.

    Director

    −$374.8K

    May 28, 2026

    11,483 sh · $32.64

  • Pande Atul10b5-1

    Director

    −$192K

    May 20, 2026

    6,000 sh · $32.00

  • Gloria Melanie

    Chief Operating Officer

    −$55.9K

    May 20, 2026

    1,698 sh · $32.95

  • Gloria Melanie

    Chief Operating Officer

    −$37.6K

    May 20, 2026

    1,168 sh · $32.15

  • Gloria Melanie

    Chief Operating Officer

    −$7.6K

    May 20, 2026

    249 sh · $30.41

  • Susman Robert Graham10b5-1

    Director

    −$68K

    May 01, 2026

    2,502 sh · $27.17

  • Girao Tiago

    Chief Financial Officer

    −$763K

    Apr 23, 2026

    25,760 sh · $29.62

  • Stout Jay S

    Chief Technology Officer

    −$81.6K

    Apr 23, 2026

    2,754 sh · $29.62

  • Gloria Melanie

    Chief Operating Officer

    −$216.6K

    Apr 08, 2026

    8,722 sh · $24.83

  • Stout Jay S

    Chief Technology Officer

    −$213.9K

    Apr 08, 2026

    8,614 sh · $24.83

  • Van Tuyl Christopher

    Chief Legal Officer

    −$128.2K

    Apr 08, 2026

    5,165 sh · $24.83

  • Stout Jay S

    Chief Technology Officer

    −$37.7K

    Apr 08, 2026

    1,518 sh · $24.83

  • Venker Eric

    Chief Executive Officer · Director

    −$308.2K

    Apr 02, 2026

    12,820 sh · $24.04

  • Venker Eric

    Chief Executive Officer · Director

    −$34.7K

    Apr 02, 2026

    1,409 sh · $24.60

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Immunovant, Inc. company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
Durham, NC
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001764013
Previously filed as
Health Sciences Acquisitions Corp

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought IMVT

What the stock actually did in the 90 days following each open-market purchase

Don't check IMVT — let it ping you

Get told the moment an insider moves on IMVT

Pro watches Immunovant, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add IMVT to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track IMVT on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read IMVT insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

INSMIOVAITCIKYMRLEGNMDGLMRUSNUVLPCVXPTGXRVMDRYTM
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are IMVT insiders buying or selling?
Between Jun 15, 2026 and Aug 28, 2026, 6 Immunovant, Inc. insiders made no open-market purchases and 24 sales worth $4.5M, a net sale of $4.5M. 4 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much IMVT stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 16 Immunovant, Inc. insiders made 2 open-market purchases worth $686.9M and 118 sales worth $21.5M. 12 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 1 purchase ($350M) and 48 sales ($15M). The largest purchase was Roivant Sciences Ltd. buying $350M on Dec 12, 2025. The largest sale was Fromkin Andrew J. selling $7.1M on May 28, 2026.
What was the largest recent IMVT insider trade?
Stout Jay S (Chief Technology Officer) sold $1.3M of IMVT stock on Jun 26, 2026 at about $38.18 a share.
When did an insider last buy IMVT shares?
No open-market purchase by a Immunovant, Inc. insider appears in the filings from Jun 15, 2026 to Aug 28, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Roivant Sciences Ltd. buying $350M on Dec 12, 2025.
Where does IMVT insider trading data come from?
From the Form 4 filings Immunovant, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.